Compare T-Rex 2X Long MSTR Daily Target ETF (MSTU) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
T-Rex 2X Long MSTR Daily Target ETF vs Sanofi SA — how do they compare? T-Rex 2X Long MSTR Daily Target ETF trades at $40.74 (market cap $809.00M), while Sanofi SA trades at $40.16 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 117.7× T-Rex 2X Long MSTR Daily Target ETF's market cap, and Sanofi SA pays a 6.01% dividend while T-Rex 2X Long MSTR Daily Target ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold T-Rex 2X Long MSTR Daily Target ETF for 18 Days and Sanofi SA for 94 Days on average.
| MSTU | SNY | |
|---|---|---|
Market Cap | $809.00M | $95.18B |
Volume | 4,577,465 | 2,995,646 |
Sector | Leveraged / Inverse | Health |
52-Week High | $451.00 | $52.34 |
52-Week Low | $14.60 | $39.51 |
Typical Hold Time | 18 Days | 94 Days |
Enterprise Value | — | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTU trades at $39.54, showing minimal daily movement with a 0.23% gain. The technical outlook is bearish based on moving averages, while oscillators present a neutral stance. Recent corporate actions include a 10:1 reverse stock split and a $0.29 dividend scheduled for August 2026. News coverage highlights the ETF's leveraged nature and recent volatility concerns.
The outlook remains cautious due to the bearish technical signals and leveraged ETF structure, which amplifies volatility. Investment opportunities exist for tactical traders seeking short-term momentum, but risks include daily rebalancing effects and potential value erosion during sustained market moves.
SNY trades at $40.17, down slightly by 0.07%. The technical outlook is bearish, with price near key support at $40. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21, and revenue for 2025 reached $46.72B. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling growth potential beyond its blockbuster drug Dupixent.
The stock presents a mixed outlook. Positive factors include consistent earnings beats, a high gross margin of 72.77%, and strategic partnerships. However, a bearish technical signal, a projected net income decline to $4.0B in 2026, and a high proportion of analyst hold ratings (51.86%) suggest caution. Key risks involve execution of new drug pipelines and future patent expirations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About T-Rex 2X Long MSTR Daily Target ETF
MSTU is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bullish (long) position in MSTR, a company known for its significant Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on MSTU →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
